Nippon India Nifty Pharma ETF
Nippon India Mutual Fund · Equity ETF · exchange-traded fund
NAV (₹), 1 Oct 2026
27.0545
1-day change
-0.48%
1Y return
21.5%
3Y CAGR
20.0%
5Y CAGR
13.1%
Max drawdown, 5Y
−21.0%
NAV history month-end NAV, ₹ · 6 Jul 2021 to 1 Oct 2026
Returns vs Equity ETF median (255 schemes) and “Sector: Healthcare & pharma” median (8)
| Period | Scheme | Category median | Sector: Healthcare & pharma median |
|---|---|---|---|
| 1 month | -1.8% | -6.5% | -3.5% |
| 3 months | 4.7% | -5.3% | 0.4% |
| 6 months | 19.8% | 5.1% | 14.7% |
| Year to date | 16.2% | -7.6% | 10.3% |
| 1 year | 21.5% | -3.4% | 12.8% |
| 3 years (CAGR) | 20.0% | 7.8% | 18.9% |
| 5 years (CAGR) | 13.1% | 7.2% | 12.8% |
| 7 years (CAGR) | n/a | 11.4% | n/a |
| 10 years (CAGR) | n/a | 11.2% | n/a |
| Since first NAV (CAGR) | 12.8% | – | – |
“Sector: Healthcare & pharma” is MFIC's grouping of Equity ETF schemes by the theme or index in their names, not an AMFI category.
Rolling returns every business-day start date
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 13.0% | 9.6% |
| 3Y rolling median | 20.5% | 14.9% |
| 3Y rolling worst | 12.3% | 6.0% |
| 3Y periods positive | 100% | 100% |
| 3Y periods ahead of benchmark | n/a | n/a |
| 5Y rolling median | 13.7% | 14.4% |
| 5Y rolling worst | 12.4% | 5.9% |
| 5Y periods ahead of benchmark | n/a | n/a |
Benchmark: none available in MFIC's free data for this category.
Risk 36 months, monthly returns, Rf 6.5%
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 15.8% | 16.8% |
| Sharpe ratio | 0.98 | 0.15 |
| Sortino ratio | 1.71 | 0.20 |
| Beta | n/a | n/a |
| Alpha (ann.) | n/a | n/a |
| Upside capture | n/a | n/a |
| Downside capture | n/a | n/a |
Drawdowns peak-to-trough falls in NAV
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −21.0% | −21.0% |
| Maximum drawdown, last 10Y | n/a | −38.1% |
| Maximum drawdown, last 5Y | −21.0% | −20.6% |
| Current drawdown | −3.2% | −11.6% |
| Recovery time of worst fall | 136 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
Fund managers and scheme facts Scheme Summary Document via AMFI
| Fund manager | Role | Managing since |
|---|---|---|
| Jitendra Tolani | Primary | 1 Feb 2025 |
Objective: The investment objective of the scheme is to provide investment returns closely corresponding to the total returns of the securities as represented by the NIFTY Pharma Index before expenses, subject to tracking errors. However, there can be no assurance or guarantee that the investment objective of the Scheme will be achieved.
Stated asset allocation: Securities constituting securities constituting Nifty Pharma Index - 95% to 100%, Money Market Instruments including TriParty Repo on governement securities or T-Bills, cash & cash equivalents or Liquid Schemes - 0% to 5%.
Benchmark (tier 1): Nifty Pharma TRI
Minimum application: In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores
Allotment date: 2 Jul 2021
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
Cost, size and riskometer as disclosed to AMFI
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), ETF | 0.00% | 0.21% |
| AUM, whole scheme (₹ crore) | 1,736 | 101 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
Official benchmark and category consistency
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 23.7% | 24.0% TRI |
| Return, 3 years (AMFI) | 20.1% | 20.4% TRI |
| Return, 5 years (AMFI) | 13.4% | 13.6% TRI |
Official benchmark: Nifty Pharma TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Equity ETF ETFs; how it is calculated.
Calendar-year returns NAV change from 31 Dec to 31 Dec
| Year | Scheme | Benchmark | Difference |
|---|---|---|---|
| 2026 YTD | 16.2% | n/a | – |
| 2025 | -2.5% | n/a | – |
| 2024 | 39.6% | n/a | – |
| 2023 | 34.4% | n/a | – |
| 2022 | -10.9% | n/a | – |
No free benchmark proxy for this category. The first year starts from the first 31 December in the scheme's history.
Monthly SIP of ₹10,000 first business day of each month, ending 1 Oct 2026
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,35,144 | 24.2% |
| 3 years | ₹3,60,000 | ₹4,56,543 | 16.0% |
| 5 years | ₹6,00,000 | ₹9,46,335 | 18.3% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
About ETF figures. All figures use the ETF's NAV as published by AMFI. Investors buy and sell ETFs on the stock exchange at the traded price, which can be above or below NAV and adds brokerage and bid-ask costs. Liquidity varies between ETFs.
Scheme facts
Category: Equity ETF
Plan / option: ETF · Growth
AMFI scheme code: 149008
ISIN: INF204KC1089
First NAV in MFIC data: 6 Jul 2021
History: 5.2 years
Portfolio holdings: see the scheme's monthly portfolio disclosure on the fund house website
Schemes that behaved similarly correlation of monthly returns, last 5 years
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| DSP Nifty Healthcare ETF | Equity ETF | 0.98 | n/a |
| Axis NIFTY Healthcare ETF | Equity ETF | 0.97 | 18.5% |
| ICICI Prudential Nifty Healthcare ETF | Equity ETF | 0.97 | 18.8% |
| Aditya Birla Sun Life Nifty Healthcare ETF | Equity ETF | 0.97 | 18.9% |
| Motilal Oswal BSE Healthcare ETF | Equity ETF | 0.96 | 20.9% |
| ICICI Prudential Nifty Alpha Low- Volatility 30 ETF | Equity ETF | 0.77 | 8.2% |
Questions about Nippon India Nifty Pharma ETF
- What is the latest NAV of Nippon India Nifty Pharma ETF?
- The NAV of the ETF was ₹27.0545 on 1 Oct 2026, as published by AMFI.
- Which category is Nippon India Nifty Pharma ETF in?
- It is classified as Equity ETF in AMFI's daily NAV file; a Equity ETF scheme tracks an equity index and trades on the stock exchange. MFIC compares it with 255 Equity ETF schemes (ETFs).
- What returns has Nippon India Nifty Pharma ETF delivered?
- Over one year the NAV changed by 21.5%. The 3-year CAGR is 20.0% (category median 7.8%) and the 5-year CAGR is 13.1% (category median 7.2%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 20.5%, the lowest was 12.3%, and 100% of 3-year periods ended with a gain.
- What was the largest fall in Nippon India Nifty Pharma ETF's NAV?
- The largest peak-to-trough fall in its available history was 21.0%; within the last five years it was 21.0% (category median 20.6%).
- How volatile is Nippon India Nifty Pharma ETF?
- Its annualised standard deviation of monthly returns over the last 36 months is 15.8%, which is below the Equity ETF category median of 16.8%.
- What would a monthly SIP in Nippon India Nifty Pharma ETF have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 5 years (60 instalments, ₹6,00,000 invested) would have been worth about ₹9,46,335 on 1 Oct 2026, an annualised return (XIRR) of 18.3%. This uses the ETF plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of Nippon India Nifty Pharma ETF?
- The total expense ratio of the ETF is 0.00% a year, as disclosed to AMFI (median of Equity ETF ETFs: 0.21%). It is already deducted from the NAV, so every return shown is after expenses.
- How large is Nippon India Nifty Pharma ETF?
- Assets under management of the whole scheme were ₹1,736 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of Nippon India Nifty Pharma ETF?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of Nippon India Nifty Pharma ETF and how has it compared?
- Its official benchmark is the Nifty Pharma TRI. Over 3 years AMFI reports a return of 20.1% for this plan against 20.4% for the benchmark total return index; over 5 years 13.4% against 13.6%. Past performance does not indicate future results.
- Who manages Nippon India Nifty Pharma ETF?
- According to its Scheme Summary Document, Nippon India Nifty Pharma ETF is managed by Jitendra Tolani (since 1 Feb 2025).
- What is the minimum investment in Nippon India Nifty Pharma ETF?
- The minimum application amount is In creation unit size of 75,000 units and in multiples thereafter However, in case of large investors, the execution value must be greater than Rs. 25 crores.
Reviewing your own mutual fund portfolio?
Integrato's team can walk you through how your current schemes have behaved, using the same data shown here. Integrato is an AMFI-registered Mutual Fund Distributor.
Follow Nippon India Nifty Pharma ETF by email
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.
Data & disclosure. Source: AMFI daily NAV file and historical NAVs via mfapi.in; calculations by MFIC, as of 1 Oct 2026. Category medians use ETFs in the same AMFI category. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance may or may not be sustained in future. This page is for research and education only and is not investment advice or a recommendation to buy, sell or hold any scheme. Integrato Financial Services Pvt. Ltd. is an AMFI-registered Mutual Fund Distributor (ARN-173155). Methodology.